| Anthony Rex Hunter | |
|---|---|
Anthony Rex Hunter
|
|
| Born | 23 Aug 1943 United Kingdom |
| Nationality | United Kingdom |
| Institutions | Salk Institute University of California, San Diego |
| Alma mater | Felsted, University of Cambridge |
| Known for | kinase |
| Notable awards | Wolf Prize in Medicine in 2005 |
Anthony Rex Hunter (born 23 Aug 1943) is a British-American biologist who is a Professor of Biology at the Salk Institute for Biological Studies and the University of California, San Diego. His research publications list his name as Tony Hunter.[1]
Contents |
Anthony R. Hunter was born in 1943 in the United Kingdom and educated at Felsted, prior to Christ's College at Cambridge University.
He received a Ph.D. from the University of Cambridge, in Cambridge, England and held a fellowship at Christ's College in Cambridge (1968–1971) and (1973–1975). From 1971 to 1973, he was a research associate of the Salk Institute for Biological Studies in La Jolla, California. He was then assistant professor 1975-78, associate professor 1978-82, professor 1982 onwards and since 2008 director of the Salk Institute Cancer Center.[2]
Dr. Hunter is one of the foremost recognized leaders in the field of cell growth control, growth factor receptors and their signal transduction pathways.
He is well-known for discovering that tyrosine phosphorylation is a fundamental mechanism for transmembrane-signal transduction in response to growth factor stimulation and that disregulation of such tyrosine phosphorylation, by activated oncogenic protein tyrosine kinases,[3] is a pivotal mechanism utilized in the malignant transformation of cells. His work is important in signaling pathways and their disorders.
He was a founder of Signal Pharmaceuticals.
He won the Wolf Prize in Medicine in 2005 for "the discovery of protein kinases that phosphorylate tyrosine residues in proteins, critical for the regulation of a wide variety of cellular events, including malignant transformation".[4]
|
||||||||